García-Piñeres Alfonso J, Hildesheim Allan, Dodd Lori, Kemp Troy J, Yang Jun, Fullmer Brandie, Harro Clayton, Lowy Douglas R, Lempicki Richard A, Pinto Ligia A
HPV Immunology Laboratory, Science Applications International Corporation-Frederick/National Cancer Institute-Frederick, Frederick, MD 21702, USA.
J Immunol. 2009 Feb 1;182(3):1706-29. doi: 10.4049/jimmunol.182.3.1706.
Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.
人乳头瘤病毒(HPV)病毒样颗粒(VLP)疫苗最近已获许可。尽管中和抗体滴度被认为是预防感染的主要效应因子,但长期疗效的早期预测指标尚未明确,对疫苗接种的先天性和适应性免疫反应仍缺乏全面了解。在此,我们使用微阵列比较了17名疫苗接种者和4名安慰剂接受者在接种前以及接受第二次免疫后1个月时,HPV-16 L1 VLP刺激的外周血单核细胞(PBMC)中的基因表达特征。接种单价HPV-16 L1 VLP疫苗与VLP刺激的PBMC中参与炎症/防御反应、细胞因子、干扰素和细胞周期途径的基因调节有关。此外,与细胞毒性(颗粒酶B、肿瘤坏死因子配体超家族成员10)和调节(吲哚胺2,3-双加氧酶、细胞毒性T淋巴细胞相关抗原4)活性相关的探针集上调。发现细胞周期蛋白D2(CCND2)和半乳糖凝集素(LGALS2)与中和抗体滴度的相关性最强。选择了22个差异表达的探针集在独立样本集中通过逆转录-聚合酶链反应(RT-PCR)进行验证。这些探针集中超过三分之二与微阵列数据一致。在接种前采集的PBMC中观察到HPV-16 L1 VLP使免疫/防御反应基因上调,特别是干扰素诱导的基因,其中许多基因在接种后进一步诱导。总之,我们确定了接种HPV-16 L1 VLP诱导的重要先天性和适应性反应相关基因。需要进一步研究以确定免疫原性和长期保护的基因表达特征,其在预测临床试验中HPV长期疫苗接种结果方面可能具有实用性。